Antengene to Unveil Cos-TCE Platform Data at SITC 2026 in Phoenix
Shanghai/Hong Kong – – October 02, 2026 -- Antengene Corporation Limited (SEHK: 6996.HK) will present preclinical results of its novel costimulatory T cell engager (Cos-TCE) platform in a Rapid Oral Abstract Presentation at the Society for Immunotherapy of Cancer Annual Meeting (SITC 2026), running November 4-8 at the Phoenix Convention Center in Arizona.
Chief Scientific Officer to present CD2-based platform data on November 6
Dr. Bing Hou, Antengene's Chief Scientific Officer, will deliver the presentation titled "A CD2-based costimulatory T cell engager platform integrating a novel CD3γε/δε-targeting antibody and steric-hindrance-based CD3 masking," filed under Abstract 15749. The session, categorized as Rapid Oral - Basic 1, is scheduled for 12:30 PM to 1:30 PM Eastern Time on November 6, corresponding to 1:30 AM to 2:30 AM Beijing time on November 7.